Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

E. J. Sorenson, A. J. Windbank, J. N. Mandrekar, W. R. Bamlet, S. H. Appel, C. Armon, P. E. Barkhaus, P. Bosch, K. Boylan, W. S. David, E. Feldman, J. Glass, L. Gutmann, J. Katz, W. King, C. A. Luciano, L. F. McCluskey, S. Nash, D. S. Newman, R. M. PascuzziE. Pioro, L. J. Sams, S. Scelsa, E. P. Simpson, S. H. Subramony, E. Tiryaki, C. A. Thornton

Research output: Contribution to journalArticlepeer-review

198 Scopus citations

Fingerprint

Dive into the research topics of 'Subcutaneous IGF-1 is not beneficial in 2-year ALS trial'. Together they form a unique fingerprint.

Medicine & Life Sciences